Waters Launches High-Speed Mass Spectrometer to Boost Multiomics Research
Event summary
- Waters Corporation introduced the Xevo MRT P10 Mass Spectrometer, a benchtop high-resolution QToF system with up to 20x higher MS/MS sensitivity and 2x faster acquisition speeds than its predecessor.
- The new system identifies up to 40% more lipids by LC-MS/MS compared to leading alternatives, advancing lipidomics research.
- The Xevo MRT P10 MS will be showcased at the 74th ASMS Conference and is expected to be available globally beginning summer 2026.
- The instrument is designed to accelerate biomarker discovery and support disease pathway identification in large-cohort biomedical research.
The big picture
Waters' new mass spectrometer addresses a critical bottleneck in high-throughput multiomics research, offering unprecedented sensitivity and speed. This launch aligns with the growing demand for advanced analytical tools in biopharmaceutical and biomedical research, positioning Waters to capture a larger share of the high-resolution mass spectrometry market. The instrument's ability to identify more lipids and accelerate biomarker discovery could significantly enhance disease research and drug development workflows.
What we're watching
- Adoption Pace
- The pace at which academic and biopharmaceutical institutions adopt the Xevo MRT P10 MS will determine its market penetration and revenue impact.
- Competitive Response
- Whether competitors like Thermo Fisher Scientific or Agilent Technologies will introduce comparable or superior technologies in response.
- Research Impact
- How the enhanced capabilities of the Xevo MRT P10 MS will affect the speed and depth of multiomics research, particularly in disease understanding and therapeutic development.
Related topics